A monoclonal immunoenzymometric assay for alpha-fetoprotein (M-AFP) was evaluated with respect to its utility in monitoring hepatocellular carcinoma (HCC) patients. Earlier (Clin Chem 1986;32:1318-22), we found this immunoassay to demonstrate abilities similar to polyclonal AFP assays, and we suggested that changes in M-AFP correlated with changes in intrahepatic tumor volume in most HCC patients. In the present study, 107 HCC patients were evaluated between 1978 and 1986. Patient demographics characterized this study population as being similar to those seen in regions with low incidence of HCC. Changes in serum M-AFP concentration correlated moderately (r = 0.55) with changes in intrahepatic tumor volume. The AFP concentration in serum was found to be a statistically significant independent predictor of survival; patients with above-normal Serum alpha-fetoprotein (AFP), the major protein in fetal circulation during early life (11), increases above the low concentrations seen in normal adults (12) in variousdisease states, including hepatic neoplasms (primary and metastatic), germ-cell tumors (12, 13), hepatitis, and cirrhosis (14). The development of quantitative immunoassays for AFP that are sufficiently sensitive to allow detection of AFP in normal serum has had one unfortunate consequence: nonspecificity in distinguishing between malignant and nonmalignant causes of moderately increased AFP concentrations. Though sensitivity for early detection of HCC with AFP was best when the upper limit of"normal" (9 ug/L) was used as the decision level, discrimination between HCC and other diseaseswas most efficient when a higher decision level (100 p.g/L) was used. Discrepancies seen between results for the monoclonal and the polyclonal assay may be accounted for in part by the presence of AFP variants (19,20) .
gent involving a two-site immunoassay was evaluated by Chan et al. (19) in patients with HCC, other malignant tumors, and various non-malignant conditions. As previously demonstrated with polyclonal-antibody AFP assays (15-18), most HCC patients had increased AFP values, and in most other diseases concentrations were lower, but there was much overlap among the disease groups.
Though sensitivity for early detection of HCC with AFP was best when the upper limit of"normal" (9 ug/L) was used as the decision level, discrimination between HCC and other diseaseswas most efficient when a higher decision level (100 p.g/L) was used. Discrepancies seen between results for the monoclonal and the polyclonal assay may be accounted for in part by the presence of AFP variants (19, 20) .
In addition to its use in the diagnosis of HCC, assay of serum AFP has also been used to monitor the course of HCC (21, 22) . In our previous study in which we used a monoclonal assay (19), preliminary data suggestedthat changes in serum APP correlatedwith changes in intrahepatic tumor volume in most 11CC patients. Here,we further evaluate the utility of monitoring HCC patients with this monoclonal AFP immunoassay (M-AFP) during treatment. Tarrytown, NY 10591) and hepatitis B serologic studies ("Abbott EIA"; Abbott Labs., North Chicago, IL 60064) were also done. Liver tumor volumes were calculated from computer-assisted tomographic (CT) scans as described by Order et al. (23) . Statistical analysis of discretedata was performed by chi-square computations.
MaterIals and Methods

Methods
Kaplan-Meier
survival analyses (24) were generated from computer softwareprovidedby the Johns Hopkins Oncology Center, which included log rank and generalized Wilcoxon calculations, as well as determination of median survival times with confidence intervals estimated by the Brookmeyer-Crowley method. Time of survival was defined as the interval from the date of initial presentation until the date of death. 
Results
AFP Distributionamong DifferentDisease Groups
A total of 1343 samples from 759 patients were analyzed for M-AFP. Figure 1 shows the distribution of the results among these patients, published previously (19). For most (77%) of the HCC cases M-AFP results were abnormal (>9 gfL), but overlapped with the normal reference interval. Most M-AFP values that were >20 g/L and <300 .ug/L in patients with benign liver disease were associatedwith hepatitis B virus (HBV) infection. 
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_. The following groups of patients were studied: hepatitis B surface antigen carrier, antibody to hepatitis B virus in the absence of HB0Ag, HB,Ag carrier with cirrhosis,anti-HB with cirrhosis,cirrhosiswith other hepatitisserology,other liver disease, and historyof liver functionunknown eight (7.5%) Oriental patients, two (1.5%) Hispanic patients, and three (2.5%) other patients.
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-, pre-treatment; 4, post-treatment. We define a significant change in a value as one 10%. Of the 67 HCC patients with values from two or more points in time, 15 (22%) showed complete agreement in directionof change of M-AFP and TV for all points and 40(59%) had at least 50% agreement. Complete disagreement was seen in 17 (25%) of the patients. These results are statistically significant (P <0.025).
Effect of a change in metastatic status. During the course of this study, eight (7%) patients experienced a change in their metastatic disease status. Seven developed metastases, and one was apparently clinically cleared of all meta- 
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Discussion
Characteristics of HCC Study Populations
Epidemiologic studies of hepatocellular carcinoma (HCC) have suggested that low-incidence and high-incidence populations exhibit many demographic and environmental differences (2). In the present population, the age incidence, sex ratio, racial distribution, and associated diseases were, as expected, consistent with that seen in low-incidence populations. The significance of these differences seen in variouspopulations is unclear, and may represent varying environmental exposures, host susceptibility, or intrinsic differences in the disease itselL Nevertheless, the importance of knowing the characteristics of the study population in HCC is not completely understood, so such data should be included in any report of this disease.
Prognostic indicators
The product limit method of Kaplan and Meier (24) was chosen over the life- (27) found an opposite trend for AFP, which was statistically insignificant; however, in their study they used a polyclonal radioimmunoassay (27) . The importance ofthis finding is not known at this time, but it could serve to determine which patients are at higher risk of recurrence and should be treated more aggressively.
Monitoring HCC with M-AFP
As shown previously by Chan et al. increases (see Figure 1) were directly associated with active hepatitis, both acute and chronic, and approximately two-thirds of those cases (see Figure 2) were directly associated with the presence of HB9Ag and anti-HBe. No similar association was demonstrated between AFP and hepatitis serology in HCC patients. However, retrospective data-gathering showed that 20% of the samples were from patients with incomplete hepatitis serology.
It is often stated that AFP synthesis is associated with liver cell regeneration (35). However, Alpert and Feller (36) did not find this to be supported in post-hepatectomy samples, and they suggested that viruses and other toxins may induce a "distinctive type of cell injury or altered hepatocyte regeneration" resulting in AFP synthesis. These data,together with other literature (34, 37, 38), suggest some association between hepatitis B infection and AFP synthesis.
The mechanism of such an association is unknown. On the other hand, the presence of virus may also result in altered cell growth, which could then be responsible either directly or indirectly for the expression of AFP. Because these changes may precedepresentation of gross neoplasia by many years, a prospective study would be needed to establish any possiblerelationshipbetween progression of serum AFP or HBV serologies, HE V-DNA integration, and tumor development.
In addition, with the recent data associating seronegativity, expression of HEy-DNA in hepatocytes, and development of hepatocellular carcinoma (40,41), dne would liketo assess if a seronegative patient with a significantly increased serum AFP, whether associated with HCC or not, exhibits HEy-DNA in hepatocytes and whether this could have any relationship to the disease prognosis or therapy. This could also provide a possible explanation for the observed discrepancy between AFP and HBV serologic status and survival seen above. That is to say, a worse prognosis may be associated with AFP synthesis related to HBV, but this association is not necessarily evident in the HBV serology because of variable expression of these serologic markers.
In conclusion, the highly lethaldisease of hepatocellular carcinoma was studied in a low-incidence population with a monoclonal immunoenzymometric serum assay for AFP.
Some correlation was seen between M-AFP concentration changes and intrahepatic tumor volume changes, and it was demonstrated to be a fairly good index to the clinical course.
Most importantly, serum AFP concentration was found to be an independent predictor of survival. The association between hepatitis B virus and AFP synthesis is unclear. With greater understanding of this relationship, bettertests can perhaps be developed for therapeutic purposes and there can be more investigative progress in prevention and cure.
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